β and p-tau have been proven to predict disease progression independently in various investigations. Both proteinopathies, according to a hypothesised framework, synergistically enhance downstream neurodegeneration. The presence of such a synergism would imply that the combined effect of A β and p-tau on AD progression is greater than the sum of their individual effects at the same level. Indeed, recent studies demonstrate that rather than neurodegeneration, the synergistic interaction between brain A and p-tau drives AD-related metabolic decline in a cognitively normal population. In the adult human brain, billions of synapses join more than a hundred billion long branching extensions of neurons to build complex chemical connections between inter-neuron circuits. Nonlinear cumulative effects of two active chemicals with similar or related consequences of their distinct activities, or active compounds with sequential or complementary activities, are known as synergistic effects.
Important Alert:
X
Title : Down’s syndrome (trisomy 21) and alzheimer disease: A common medical and scientific fight
London Jacqueline, Paris Diderot University, France
Title : Quality of life children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Electrophysiology and alzheimer's pathology: A scoping review on eeg correlations with CSF biomarkers
Charikleia Karastamati, University of Pavia, Italy
Title : The vital role of care homes in supporting individuals with neurological conditions
Akankunda Veronicah, Executive Director, Uganda
Title : Semantic-based memory-encoding strategy in enhancing cognitive function and daily task performance for older adults with mild cognitive impairment: A pilot non-randomised
Karen P Y Liu, Western Sydney University, Hong Kong
Title : Memory should be the primary endpoint in early AD
Matthias W Riepe, Ulm University, Germany